Lung Cancer Clinical Studies NISCHR CRC
|
|
- Joshua Bradford
- 8 years ago
- Views:
Transcription
1 Lung Cancer Clinical Studies NISCHR CRC September 2010
2 Table of Contents 1 RECRUITMENT SUMMARY OF RECRUITMENT IN WALES INTO UK APPROVED LUNG CANCER STUDIES ALL WALES NCRN REPORTED LUNG CANCER STUDIES RECRUITMENT BY STUDY AND HOSPITAL (FINANCIAL YEAR 2009/10) COMPARISON OF LUNG CANCER STUDIES RECRUITMENT WITH NETWORKS IN ENGLAND 2009/ APPENDICES APPENDIX 1: UK PORTFOLIO OF STUDIES (NCRN APPROVED)...7 Current Open UK Approved Studies by Disease Site (September 2010)..7 Current Open Approved Studies by Disease Site in Wales (September 2010) APPENDIX 2: ALL WALES NCRN REPORTED LUNG RECRUITMENT BY STUDY AND MONTH (FINANCIAL YEAR 2009/10) BY REGIONAL NETWORK APPENDIX 3: NCRN LUNG PORTFOLIO UK & WALES APPENDIX 4: CONTACTS...12
3 1 Recruitment 1.1 Summary of Recruitment in Wales into UK Approved Lung Cancer Studies 2004/ / / / / /10 N Wales SE Wales SW Wales TOTAL Recruitment in Wales into UK Approved Lung Cancer Studies Number Recruited N Wales SE Wales SW Wales / / / / / /10 Financial Year All data extracted from UKCRN Database during September During UKCRN have experienced difficulties with the completeness of Study activity reporting, this is likely to have resulted in under-reporting of WCRN Study activity data. Page 3 of 12
4 Randomised (RCT) vs. Non-randomised (Other) Lung Cancer Trials in Wales - Regional Breakdown ( ) Number Recruited N Wales SE Wales SW Wales RCT Other RCT Other RCT Other RCT Other 2006/ / / /2010 Financial Year 1.2 All Wales NCRN Reported Lung Cancer Studies Recruitment by Study and Hospital (Financial Year 2009/10) North Wales BANG GCHR WREX Total BTOG2 (Nov-09)-C FRAGMATIC (Jun-10) MALCS (Mesothelioma and Lung Cancer Study) (Jul-10) TACTIC (Jun-10) Total North Wales hospital codes: BANG Bangor Hospital GCHR Glan Clwyd Hospital, Rhyl WREX Wrexham Hospital Page 4 of 12
5 South East Wales POW CHW UHWC VEL LLAN NEVH PCMT RGH RGL Total BTOG2 (Nov-09)-C FRAGMATIC (Jun-10) LungStar (Jul-10) MALCS (Mesothelioma and Lung Cancer Study) (Jul-10) ReSoLuCENT (Jun-10) TACTIC (Jun-10) Total South East hospital codes: POW Princess of Wales, Bridgend CHW Children s Hospital, Cardiff UHWC University Hospital of Wales, Cardiff VEL Velindre Hospital, Cardiff LLAN Llandough, Cardiff NEVH Nevill Hall, Abergavenny PCMT Prince Charles, Merthyr Tydfil RGH Royal Gwent, Newport RGL Royal Glamorgan, Pontypridd South West Wales PPHL WWGH BRON MOR SING WYBH Total ET Trial (Jul-10) FRAGMATIC (Jun-10) LungStar (Jul-10) MALCS (Mesothelioma and Lung Cancer Study) (Jul-10) Total South West hospital codes: PPHL Prince Phillip, Llanelli WWGH West Wales, Carmarthen BRON Bronglais, Aberystwyth MOR Morriston, Swansea SING Singleton, Swansea WYBH Withybush, Haverfordwest NPT Neath / Port Talbot NB. Bracketed dates indicate month of last recruitment upload to UKCRN for that particular study. Page 5 of 12
6 1.3 Comparison of Lung Cancer Studies Recruitment with Networks in England 2009/10 Region Page 6 of 12 Network Population (m) Patients Recruited to Lung Studies England Arden NCRN 1 56 Avon, Somerset & Wiltshire NCRN Black Country NCRN 1 0 Central South Coast NCRN Derby/Burton NCRN Dorset NCRN Essex NCRN* Greater Manchester & Cheshire NCRN Greater Midlands NCRN* Humber and Yorkshire Coast NCRN 1 49 Kent & Medway NCRN Lancashire and South Cumbria NCRN Leics, Northants & Rutland NCRN Merseyside & Cheshire NCRN Mid Anglia NCRN 1 4 Mid Trent NCRN Mount Vernon NCRN Norfolk and Waveney NCRN North East London NCRN North London NCRN North of England North NCRN 2 39 North of England - South NCRN 1 24 North Trent NCRN North West Midlands NCRN Pan Birmingham NCRN Peninsula NCRN South East London NCRN South Essex NCRN South West London NCRN Surrey, W Sussex & Hampshire NCRN Sussex NCRN 1 15 Thames Valley NCRN Three Counties NCRN Unknown NCRN West Anglia NCRN West London NCRN Yorkshire NCRN England Total Wales Wales - North Wales - South East Wales - South West Wales Total * = Greater Midlands and Essex populations excluded from England population total for duplication reasons as these have been recently formed and are made up of other NCRNs listed in the table.
7 2 Appendices 2.1 Appendix 1: UK Portfolio of Studies (NCRN Approved) Current Open UK Approved Studies by Disease Site (September 2010) Cancer Site Number of Studies Percentage Brain 8 2% Breast 74 19% CCLG 32 8% Colorectal 29 7% Gynaecological 23 6% Haematological 34 9% Head & Neck 18 5% Lung 32 8% Lymphoma 23 6% Palliative Care 18 5% Sarcoma 10 3% Skin 9 2% Upper GI 36 9% Urology 43 11% Current Open Approved Studies by Disease Site in Wales (September 2010) Cancer Site Number of Studies Percentage Brain 2 1% Breast 30 22% CCLG 9 7% Colorectal 11 8% Gynaecological 5 4% Haematological 13 9% Head & Neck 6 4% Lung 12 9% Lymphoma 13 9% Palliative Care 2 1% Sarcoma 1 <1% Skin 3 2% Upper GI 17 12% Urology 14 10% Page 7 of 12
8 2.2 Appendix 2: All Wales NCRN Reported Lung Recruitment by Study and Month (Financial Year 2009/10) by Regional Network North Wales Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Total BTOG2 (Nov-09) FRAGMATIC (Jun-10) LungStar MALCS (Mesothelioma and Lung Cancer Study) (Jul-10) NCRN017 - INDUSTRY STUDY SOCCAR TACTIC (Jun-10) TOPICAL Total South East Wales Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Total BTOG2 (Nov-09) ET Trial FRAGMATIC (Jun-10) LungStar (Jul-10) MALCS (Mesothelioma and Lung Cancer Study) (Jul-10) ReSoLuCENT (Jun-10) TACTIC (Jun-10) TIME TIPS TOPICAL Total South West Wales Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Total ET Trial (Jul-10) FRAGMATIC (Jun-10) LungStar (Jul-10) Page 8 of 12
9 MALCS (Mesothelioma and Lung Cancer Study) (Jul-10) TOPICAL Total GRAND TOTAL NB. Dates in brackets show last month of recruitment upload to UKCRN database for that particular study. 2.3 Appendix 3: NCRN Lung Portfolio UK & Wales Open Studies Acronym Description Open in Wales Patient/s recruited to date in Wales ASyMS-R Improving the symptom experience of patients with lung cancer receiving radiotherapy: Advance Symptom Management System for Radiotherapy CLUB Cancer of the Lung Biomarkers "The CLUB Trial" CONVERT A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status ET Trial A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification, in patients with advanced/metastatic non-small cell lung cancer Experiences of episodic breathlessness Experiences of episodic breathlessness in patients with advanced disease FLT PET to assess tumour proliferation during radical radiotherapy CT-18FLT- PET sequential imaging protocol to assess tumor proliferation during radical radiotherapy FRAGMATIC A randomised phase III clinical trial investigating the effect of FRAGMin Added to standard Therapy In patients with lung Cancer Living Well with Lung Cancer Living well with lung cancer: evaluating the effectiveness of a sustainable model of follow-up care LLP Liverpool Lung Project Lung-BOOST A New Pathway With BronchOscopic or Oesophageal Ultrasound for Lung Cancer Diagnosis and Staging: A Randomised Controlled Trial (Lung-BOOST) Lung-SEARCH A randomised controlled trial of surveillance for the early detection of lung cancer in a high-risk group. LungStar A multicentre phase III randomised double blind placebo contolled trial of pravastatin added to firstline standard chemotherapy in patients with small cell lung cancer Page 9 of 12
10 MALCS (Mesothelioma and Lung Cancer Study) A population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and women MEDLUNG Early detection of lung cancer: metabolic biomarkers for high risk screening MESOVATS Prospective randomised controlled trial of videoassisted thoracoscopic (VATS) cytoreductive pleurectomy compared to talc pleurodesis in patients with suspected or proven malignant mesothelioma. Modafinil for Fatigue in Lung Cancer Modafinil for the treatment of fatigue in lung cancer: a multicentre, randomised, double-blinded, placebo controlled trial NCRN019 - INDUSTRY STUDY A Double-Blind, Randomised, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Recmage-A3 + As15 Antigen Specific Cancer Immunotherapeutic As Adjuvant Therapy In Patients With Resectable Mage-A3-Positive Non- Small Cell Lung Cancer NCRN032 - INDUSTRY STUDY Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non- Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology NCRN073 A Phase III, multi-center, placeboâ controlled trial of Sorafenib (BAY ) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens NCRN095 (FORTIS-M) FORTIS-M: A Phase 3, randomised, double-blind, placebo-controlled study of oral talactoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior treatment regimens NCRN144 - TCD11420 A randomised phase 2 trial of Gemcitabine/Cisplatin with or without SAR (a PARP1 inhibitor) in patients previously untreated for advanced non-small cell lung cancer NMES trial Is neuromuscular electrical stimulation an acceptable and feasible supportive therapy for patients with non-small cell lung cancer receiving palliative chemotherapy? Primary Care and Lung Cancer Follow Up QUARTZ ReSoLuCENT RESTORE-AIR What is the optimal role for primary care in the management and follow-up of patients with lung cancer? A phase III multicentre randomised controlled trial to assess whether optimal supportive care (including dexamethasone) alone is as effective as optimal supportive care (including dexamethasone) and whole brain radiotherapy (WBRT) in the treatment of patients with inoperable brain metastases from non-small cell lung cancer (NSCLC). Resource for the Study of Lung Cancer Epidemiology in North Trent Randomised Evaluation of STents to Open REstricted AIRways in patients with centrally placed non-small cell lung cancer Page 10 of 12
11 TACTIC A randomised phase II double blind placebo controlled trial of Whole Brain Radiotherapy (WBRT) and Tarceva (OSI-774, erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) with brain metastases TIPS The Inhaled Particles Study Tumour Angiogenesis Tumour Angiogenesis in Non-small cell Lung, Colorectal and Breast Cancer: Radiology- Pathology and Prognostic Correlation Studies in Set-up Acronym Description CHART-ED Continuous Hyperfractionated Accelerated Radiotherapy - Escalated Dose Study IDEAL-CRT Lung ART Qualitative interviews with lung cancer patients Supportive Care Intervention for Lung Cancer Patients and Caregivers UKLS Isotoxic Dose Escalation and Acceleration in Lung Cancer ChemoRadiotherapy - A phase I/II trial of concurrent chemoradiation with dose-escalted radiotherapy in patients with stage II or stage III Non-Small Cell Lung Cancer Phase III study comparing post-operative conformal radiotherapy to no postoperative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 Involvement (EORTC ) Interviewing surgically treated lung cancer patients about their physical and psychological health, and their views about ways the national health service can help them rehabilitate. A non-pharmacological supportive care intervention for patients with lung cancer and their caregivers in the management of the respiratory distress symptom cluster UK Lung Cancer Screening Trial (UKLS) - Feasibility study and protocol development Page 11 of 12
12 2.4 Appendix 4: Contacts Research Network Managers and Clinical Leads Position Contact Name Telephone North Wales Network Manager North Wales Clinical Lead Jackie Morris Dr Simon Gollins South West Wales Network Manager Jayne Caparros wales.nhs.uk South West Wales Clinical Lead Dr Gian Filippo Bertelli wales.nhs.uk ext South East Wales Network Manager Sara Shankland wales.nhs.uk South East Wales Clinical Lead Dr John Staffurth ext Clinical Research Centre contact details Position Contact Name Telephone Director Professor John Wagstaff Associate Director Libby Batt Training & Development Manager Information Systems Specialist PA to Associate Director Zoe Whale Kumari Podila Sue Edwards Please send feedback on this report to Kumari Podila, Information Systems Specialist (WCTN). Page 12 of 12
Lung SSG 6 th May 2015 Research
Lung SSG 6 th May 2015 Research Wendy Cook, Research Delivery Manager dd/mm/yyyy Delivering clinical research to make patients, and the NHS, better South West Peninsula CRN Hospital Yeovil District Hospital
More informationQuality in Nursing Clinical Nurse Specialists in Cancer Care; Provision, Proportion and Performance
Ensuring Better Treatment National Cancer Action Team Part of the National Cancer Programme Quality in Nursing Clinical Nurse Specialists in Cancer Care; Provision, Proportion and Performance A census
More informationCancer National Specialist Advisory Group WALES LUNG CANCER DATA REPORT FOR PATIENTS FIRST SEEN BY LUNG CANCER TEAMS IN 2009 AND 2010
Cancer National Specialist Advisory Group WALES LUNG CANCER DATA REPORT FOR PATIENTS FIRST SEEN BY LUNG CANCER TEAMS IN 2009 AND 2010 Published 2012 Preface The first Wales Lung Cancer Report using prospectively
More informationWaterloo Road London SE1 8UG. 20 March 2013. Trust Chief Executives Clinical Commissioning Group Leaders Directors of Public Health
DH Gateway Ref 18853 20 March 2013 133-155 Wellington House Waterloo Road London SE1 8UG To: Copied to: Trust Chief Executives Clinical Commissioning Group Leaders Directors of Public Health NHS Foundation
More informationNational Cancer Rehabilitation Pathways. Rachel Atkinson AHP Lead May 2011
National Cancer Rehabilitation Pathways Rachel Atkinson AHP Lead May 2011 National Cancer and Palliative Care Rehabilitation workforce Project One of the objectives was to produce 9 tumour specific, evidence
More informationHow To Treat Mesothelioma
Mesothelioma in the UK Liz Darlison Mesothelioma UK The National Macmillan Mesothelioma Resource Centre June 2010 Mesothelioma Applied Research Foundation - 2010 www.curemeso.org Contents Size of Mesothelioma
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationPOLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
More informationCARDIAC REHABILITATION PROGRAMME FINDER WALES A-Z BY COUNTY
CARDIAC REHABILITATION PROGRAMME FINDER WALES A-Z BY COUNTY Programme: North Gwent Cardiac Rehabiltiation and Aftercare, Abergavenny Contact: Suzanne Indge Telephone: 01873 732511 Suzanne.Indge@wales.nhs.uk
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationClinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More information3.0 With final Comments for presentation at Sub Group Meeting 24. 24.11.10
Guideline for the Treatment of Lung Cancer Version History 2.0 Endorsed by the Governance Committee as treatment of lung cancer 27.07.09 with radiotherapy and chemotherapy. 2.1 Re-written to include the
More informationAT&T Global Network Client for Windows Product Support Matrix January 29, 2015
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationPlease see the LUCADA data manual v3.1.3, available in the downloads section
National Lung Cancer Audit Frequently Asked Questions What dataset should be used? Please see the LUCADA data manual v3.1.3, available in the downloads section What does LUCADA stand for? LUCADA stands
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationTreatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline An ASCO Endorsement of Treatment of Small Cell Lung Cancer:
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation Document Title Clinical Management Protocol Children s Hepatic Tumours Document Date July 2010 Document Purpose Authors Modalities of treatment
More informationFEATURES LIST 2012. Simon Quantrill Sharon Quantrill m: 07825 186873 m: 07825 290418 e: simon@q2design.co.uk e: sharon@q2design.co.uk.
FEATURES LIST 2012 Simon Quantrill Sharon Quantrill m: 07825 186873 m: 07825 290418 e: simon@q2design.co.uk e: sharon@q2design.co.uk t: 01789 730833 www.q2design.co.uk FEATURES: january 2012 Midlands Business
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationREPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
More informationEVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1
COMPENDIA TRANSPARENCY TRACKING FORM DATE: MAY 2015 PACKET: 111 DRUG: INDICATION: Vinorelbine Tartrate Malignant pleural mesothelioma COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize
More informationTreatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians
Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development
More informationCLL Support Associa/on up date. What, if you need treatment. Anna Schuh Consultant Haematologist Oxford University Hospitals
CLL Support Associa/on up date What, if you need treatment. Anna Schuh Consultant Haematologist Oxford University Hospitals Establishing the Diagnosis Blood film: small mature lymphocytes and smear cells
More information4.8 Lung cancer. 4.8.5 In the UK, three fractionation regimens are most commonly used:
4.8 Lung cancer 4.8.1 In 2005, both NICE (National Institute for Health and Clinical Excellence) and SIGN (Scottish Intercollegiate Guidelines Network) published guidelines on the management of lung cancer.
More informationCOMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER
COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards
More informationCity Focus: Glasgow, Q3 2011
City Focus: Glasgow, Q3 2011 Part of The Serviced Office Review Series officebroker.com City Focus - Central Glasgow Q3 2011 City Focus reports - part of The Serviced Office Review series produced exclusively
More informationCancer patients waiting for potentially live-saving treatments in UK
Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.
More informationthe standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009
Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy
More informationPre-workshop exercise
Setting research priorities for mesothelioma workshop 10 th November 2014 Pre-workshop exercise Your individual ranking of unanswered questions about the diagnosis, treatment and care of mesothelioma Please
More informationREPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer
More informationHow treatment is planned Giving your consent The benefits and disadvantages of treatment Second opinion
Treatment overview for lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 5. Contents How
More informationRadiation Therapy in the Treatment of
Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:
More informationRadiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationList of approved programmes approved mental health professionals
Education and Training Committee 12 June 2012 List of approved programmes approved mental health professionals Executive summary and recommendations This paper provides Committee with an update on the
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationChapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
More informationLung Cancer & Mesothelioma 2011-2015
Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic
More informationMOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationLatest developments in management. Gianfilippo Bertelli Consultant Medical Oncologist Swansea
Latest developments in management Gianfilippo Bertelli Consultant Medical Oncologist Swansea Optimizing management of ovarian cancer in South Wales Diagnosis and referral pathways: Role of GPs, gynaecologists,
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More informationAdvanced Lung Cancer Treatment - Chemotherapy vs Radiotherapy
Which treatment for advanced lung cancer This information tells you about the treatments for advanced lung cancer. Chemotherapy and radiotherapy can both be used to treat advanced lung cancer. They can
More informationLung NSSG Annual Report 2011/12 Agreement Cover Sheet
This Annual Report has been agreed by: Lung NSSG Annual Report 2011/12 Agreement Cover Sheet Position: Name: Chair of the NSSG Dr Duncan Powrie Organisation: Date Agreed: 9 th May 2012. Southend University
More informationThe epidemiology and treatment of mesothelioma in South East England 1985 2002
The epidemiology and treatment of mesothelioma in South East England 1985 2002 V Mak, E Davies, V Putcha, B Choodari-Oskooei, H Møller King s College London, Thames Cancer Registry, London, UK Correspondence
More informationCancer Patient Experience Survey: Insight Report and League Table 2014
Cancer Patient Experience Survey: Insight Report and League Table 2014 October 2014 Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of Man (604).
More informationLondon Cancer. Mesothelioma Lung Protocols
London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta
More informationNon-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide
More informationRapid review of current service provision following cancer treatment
NHS NHS Improvement CANCER DIAGNOSTICS NHS Improvement Rapid review of current service provision following cancer treatment HEART LUNG STROKE Acknowledgement NHS Improvement would like to thank all the
More informationPolice Force Address Phone Fax Email Mouchel Business Services penmail@mouchel.com 01642 727333 01642 727989 Middlesbrough TS1 9EE
Police Force Address Phone Fax Email National Crime Agency Avon and Somerset Devon County Council, Peninsula Pensions, Great Moor House, Bittern Road, Sowton Industrial Estate, Exeter EX2 7NL 01392 383000
More informationCase 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8
Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138 Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 2 of 138 Domain Name: CELLULARVERISON.COM Updated Date: 12-dec-2007
More informationAnalysis One Code Desc. Transaction Amount. Fiscal Period
Analysis One Code Desc Transaction Amount Fiscal Period 57.63 Oct-12 12.13 Oct-12-38.90 Oct-12-773.00 Oct-12-800.00 Oct-12-187.00 Oct-12-82.00 Oct-12-82.00 Oct-12-110.00 Oct-12-1115.25 Oct-12-71.00 Oct-12-41.00
More informationMoving forward, where are we with Clinical Trials?
Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where
More informationTreatment Routes in Prostate Cancer Urological Cancers SSCRG
1 Treatment Routes in Prostate Cancer Urological Cancers SSCRG Introduction To better understand outcome measures, it is necessary to analyse what treatment pathway a patient has followed after diagnosis.
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationMASTER LIST OF QUALIFICATIONS ASSESSED
COUNTRY SCOPE EDUCATIONAL INSTITUTE QUALIFICATION GAINED GRADUATION YEAR Charles Sturt University NSW Bachelor of Applied Science () Conversion Queensland University of B. Applied Science (Medical ) Queensland
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More information2010 National Survey. Newham University Hospital NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More informationMesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology
MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image
More informationHISTORICAL LIST OF ALL SCHEMES, COURSES AND PROGRAMMES RECOGNISED FROM 1945 ONWARDS
HISTORICAL LIST OF ALL SCHEMES, COURSES AND PROGRAMMES RECOGNISED FROM 1945 ONWARDS If you are checking whether a qualification has professional status and it does not appear on this list, please also
More informationMedication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
More informationSAKK Lung Cancer Group. Current activities and future projects
SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation
More informationAbout lung cancer. Contents. The lungs
This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 7. The lungs Contents The lungs Types of lung cancer
More information2015/16 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)-
2015/16 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)- SECTION B PART 1 - SERVICE SPECIFICATION FOR LUNG CANCER Service specification
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationSocial Media Strategy 2015-16
Social Media Strategy 2015-16 We don t have a choice whether we do social media, the question is how well we do it [Erik Qualman, 2010, Socialnomics] Introduction The CRC has previously been active on
More informationMesothelioma Framework
Gateway Ref: 7907 Mesothelioma Framework Advice for the NHS on how to organise services for Malignant Pleural Mesothelioma (MPM) patients to improve quality of care across the country 27 February 2007
More informationErlotinib for the treatment of non-small cell lung cancer. Report from the Decision Support Unit in response to additional data submitted by Roche
Erlotinib for the treatment of non-small cell lung cancer Report from the Decision Support Unit in response to additional data submitted by Roche 10 th January 2008 Part 1: A Sutton. Critique of the network
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationCOMMISSIONING SUPPORT BUSINESS REVIEW CHECKPOINT TWO OUTCOMES
COMMISSIONING SUPPORT BUSINESS REVIEW CHECKPOINT TWO OUTCOMES 14 May 2012 1 Purpose Over the last six weeks the NHS Commissioning Board Authority has been undertaking the second checkpoint of the commissioning
More informationFive Year Rental Index 2008 to 2012
Five Year Rental Index 2008 to 2012 Contents Belvoir Rental Index 2008 to 2012... 3 Introduction... 3 Report Highlights... 5 National Rental Trends... 6 Rents from a Tenant s perspective... 7 Rents from
More informationScottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
More informationREFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets
More informationMedical Oncology. Rotation Goals & Objectives for rotating residents. General Objectives THE UNIVERSITY OF BRITISH COLUMBIA
THE UNIVERSITY OF BRITISH COLUMBIA Department of Urologic Sciences Faculty of Medicine Gordon & Leslie Diamond Health Care Centre Level 6, 2775 Laurel Street Vancouver, BC, Canada V5Z 1M9 Tel: (604) 875-4301
More informationProposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer
31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally
More informationBritish Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015
0116 250 2811 dawn.mckinley@uhl-tr.nhs.uk www.btog.org @BTOGORG British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 BTOG s Aim BTOG is the multi-disciplinary group for professionals
More informationEnhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017
From -JAN- To -JUN- -JAN- VIRP Page Period Period Period -JAN- 8 -JAN- 8 9 -JAN- 8 8 -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -FEB- : days
More informationThis factsheet aims to outline the characteristics of some rare lung cancers, and highlight where each type of lung cancer may be different.
There are several different kinds of lung cancer, often referred to as lung cancer subtypes. Some of these occur more often than others. In this factsheet we will specifically look at the subtypes of cancers
More informationDefinition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products (NIMPs)
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products
More informationSpecialist adult cancer nurses in England
Specialist adult cancer nurses in England A census of the specialist adult cancer nursing workforce in the UK, 2014 2 Contents Foreword 4 1. Introduction 6 1.1 Background 6 1.2 Methods 7 1.3 Selection
More informationREPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group Educational session Treatment of stage III non-small cell lung cancer (NSCLC) in
More informationThe factors that affect HCA routes into nurse training
The factors that affect HCA routes into nurse training author Agnes Hibbert, PhD, MSc, BSc, RN, CertEd, is a health care education consultant. Abstract Hibbert, A. (2006) The factors that affect HCA routes
More informationPost-operative intrapleural chemotherapy for mesothelioma
Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy
More informationInternational Journal of Case Reports in Medicine
International Journal of Case Reports in Medicine Vol. 2013 (2013), Article ID 409830, 15 minipages. DOI:10.5171/2013.409830 www.ibimapublishing.com Copyright 2013 Andrew Thomas Low, Iain Smith and Simon
More informationQualifying Award Mode of study Validating body (if different from
Social work applicants must have the following to be able to Register Name of education provider of Name of programme (including different historical programme award levels e.g. MSc and Pg Dip) Anglia
More informationCancer Patient Experience Survey: Insight Report and League Table 2012 13
Cancer Patient Experience Survey: Insight Report and League Table 2012 13 September 2013 Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of
More informationClinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines
Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year
More informationList of approved programmes social workers in England
Education and Training Committee 12 June 2012 List of approved programmes social workers in England Executive summary and recommendations This paper provides Committee with an update on the legislation
More informationCancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
More informationExtrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos
More informationcars and buses/coaches had much lower casualty rates of 241 and 151 per billion passenger kilometres, respectively,
Provisional 1 monthly topic of interest: admitted patient care emergency admissions 2 and unplanned accident and emergency attendances 3 caused by road traffic accidents This report focuses on hospital
More information